Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $34.00 | Market Perform → Outperform | BMO Capital Markets |
| 4/30/2024 | $19.00 | Buy | Guggenheim |
| 6/17/2022 | $7.00 | Outperform | BMO Capital Markets |
| 6/9/2022 | Outperform → Mkt Perform | William Blair | |
| 9/10/2021 | $23.00 → $26.00 | Buy | Stifel |
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
SCHEDULE 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a late breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress being held May 7-10, 2025, in Amsterdam, Netherlands. "We are pleased to share initial safety data from the ELIMINATE-B trial for PBGENE-HBV at this year's EASL congress. Since initiating the trial, we have made rap